Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912091 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CTSBPDE7APDE7B | |
| SCHEMBL8903476 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CYP3A4PDE7APDE7BTSHR | |
| SCHEMBL1494433 | 0.82 | GPR35 (0.47) | ALDH1A1CYP3A4PDE7APDE7BTSHR | |
| SCHEMBL204939 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CTSBPDE7APDE7B | |
| SCHEMBL29706644 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBTSHRMAPK1 | |
| SCHEMBL2783704 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4CTSBTSHRMAPK1 | |
| SCHEMBL4695676 | 0.78 | ALDH1A1 (0.53) | ALDH1A1CYP3A4PDE7APDE7BTSHR | |
| SCHEMBL20535873 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CYP3A4PDE7APDE7BTSHR | |
| SCHEMBL3011561 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CTSBPDE7APDE7B | |
| SCHEMBL13363907 | 0.78 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CTSBPDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4596551-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | Trasveda Ltd. (KY) | 2025-08-06 | — | — | EP | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024067714-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | 泰励生物科技（上海）有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| CN-116425721-B | Bicyclic compounds as MAT2A inhibitors | 艾立康药业股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024026419-A1 | QUINOXALINE DERIVATIVES AS PIK3 ALPHA MODULATORS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-116848100-A | NOTCH inhibitors and uses thereof | 干细胞协同疗法有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008144275-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-5071995-A | Excellent ultraviolet absorbability for polyesters and polyamides; high thermal stability | KURARAY CO., LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| EP-0363839-A1 | 2-hydroxyphenylbenzotriazol compounds and the use thereof | KURARAY CO., LTD. (JP) | 1990-04-18 | — | — | EP | disclosed |
| US-4053527-A | REACTING HALONITROANILINES WITH ALCOHOLS AND NITROSATING AGENTS ION | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | ALDH1A1 1598/4885CYP3A4 18/4885CTSB 1349/4885 |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | ALDH1A1 1677/4885CYP3A4 60/4885CTSB 2337/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | ALDH1A1 2680/4885CYP3A4 24/4885CTSB 478/4885 |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | ALDH1A1 2558/4885CYP3A4 24/4885CTSB 404/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | ALDH1A1 1173/4885CYP3A4 23/4885CTSB 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.